Arcturus Therapeutics (US.ARCT)
资本配置审计 · 期间： 2011 – 2026
核心指标
US.ARCT · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 100.0% | → |
| ROE | -29.5% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.13 | ↓ |
| Gross Margin | 0.0% | ↓ |
US.ARCT (Arcturus Therapeutics) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 100.0% → ROE -29.5% ↓ Cash Conversion - → D/E Ratio 0.13 ↓ Gross Margin 0.0% ↓
核心指标
US.ARCT (Arcturus Therapeutics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 100.0% →ROE -29.5% ↓Cash Conversion - →D/E Ratio 0.13 ↓Gross Margin 0.0% ↓免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies